Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
Conditions:   Renal Cell Carcinoma;   Metastatic Castration-resistant Prostate Cancer;   Urothelial Carcinoma;   Solid Tumor
Interventions:   Drug: XL092;   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Bempegaldesleukin
Sponsor:   Exelixis
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 5, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments